Welcome to our dedicated page for Dyne Therapeutics SEC filings (Ticker: DYN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dyne Therapeutics, Inc. filings document regulatory disclosures for a clinical-stage neuromuscular disease company advancing FORCE platform programs. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary cash-resource disclosures, investor presentation materials, clinical and FDA-related updates, and other business highlights tied to Duchenne muscular dystrophy and myotonic dystrophy type 1 programs.
The company’s definitive proxy materials cover board structure, director elections, executive compensation, equity awards, stockholder voting matters and governance practices. Other filings address board appointments, non-employee director compensation arrangements and Nasdaq-related inducement equity awards.
Dyne Therapeutics, Inc. is conducting a primary offering of $300,000,000 of common stock, with a 30‑day option for underwriters to buy up to an additional $45,000,000 of common stock. Its shares trade on the Nasdaq Global Select Market under the symbol DYN; the last reported sale price on July 20, 2026 was $23.45 per share.
The company is a clinical‑stage developer of therapies for genetically driven neuromuscular diseases built on its FORCE platform, with lead programs in Duchenne muscular dystrophy (z‑rostudirsen) and myotonic dystrophy type 1 (z‑basivarsen), both in global Phase 3 trials. The FDA has accepted a biologics license application for z‑rostudirsen, granted Priority Review, and set a PDUFA target action date of January 21, 2027.
Dyne plans to use the equity proceeds, together with existing cash and a recently drawn $50.0 million term loan from Hercules, to fund clinical development, regulatory work, manufacturing and commercial build‑out, platform and pipeline R&D, and general corporate purposes. Management currently expects these resources to fund operating expenses, debt service and capital expenditures into the second quarter of 2028, subject to business and development outcomes.
Dyne Therapeutics, Inc. announced that the U.S. Food and Drug Administration has accepted for review its biologics license application for zeleciment rostudirsen (z‑rostudirsen, also known as DYNE‑251) to treat individuals with Duchenne muscular dystrophy amenable to exon 51 skipping. The FDA granted Priority Review and set a Prescription Drug User Fee Act target action date of January 21, 2027.
The company stated it continues to expect a potential U.S. launch of z‑rostudirsen in the first quarter of 2027, assuming approval is received on this anticipated timeline. Dyne also emphasized that these expectations are forward‑looking and subject to substantial risks and uncertainties, including clinical, regulatory and financing factors described in its SEC reports.
Dyne Therapeutics, Inc. director-affiliated venture funds completed open-market sales of a combined 777,451 shares of common stock on July 6–7, 2026. The trades, at weighted-average prices between about $22.79 and $23.62 per share, were executed under a Rule 10b5-1 trading plan adopted on March 19, 2026.
The shares were sold by Atlas-managed funds, including Atlas Venture Fund XI and Atlas Venture Opportunity Funds, in which director Jason P. Rhodes participates through general partner entities. He disclaims Section 16 beneficial ownership beyond any pecuniary interest. After the transactions, these funds continue to hold multimillion-share positions, such as 2,962 shares in one Atlas vehicle.